Bioptik Technology Incorporation

TPEX:4161 Stock Report

Market Cap: NT$1.8b

Bioptik Technology Incorporation Past Earnings Performance

Past criteria checks 4/6

Bioptik Technology Incorporation has been growing earnings at an average annual rate of 62.3%, while the Medical Equipment industry saw earnings growing at 9.6% annually. Revenues have been growing at an average rate of 11.8% per year. Bioptik Technology Incorporation's return on equity is 11.3%, and it has net margins of 11.3%.

Key information

62.3%

Earnings growth rate

62.2%

EPS growth rate

Medical Equipment Industry Growth11.5%
Revenue growth rate11.8%
Return on equity11.3%
Net Margin11.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Do Investors Have Good Reason To Be Wary Of Bioptik Technology Incorporation's (GTSM:4161) 1.2% Dividend Yield?

Apr 12
Do Investors Have Good Reason To Be Wary Of Bioptik Technology Incorporation's (GTSM:4161) 1.2% Dividend Yield?

Bioptik Technology Incorporation (GTSM:4161) Is Making Moderate Use Of Debt

Feb 16
Bioptik Technology Incorporation (GTSM:4161) Is Making Moderate Use Of Debt

Is Bioptik Technology Incorporation (GTSM:4161) A Strong Dividend Stock?

Dec 25
Is Bioptik Technology Incorporation (GTSM:4161) A Strong Dividend Stock?

Revenue & Expenses Breakdown

How Bioptik Technology Incorporation makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:4161 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248841009475
30 Jun 249091139275
31 Mar 24891968573
31 Dec 23829867871
30 Sep 23825688469
30 Jun 23816658464
31 Mar 23776548159
31 Dec 22768488058
30 Sep 22727377854
30 Jun 22699197755
31 Mar 22716237852
31 Dec 21738237949
30 Sep 2167817545
30 Jun 21582-347544
31 Mar 21525-447545
31 Dec 20486-607550
30 Sep 20513-517761
30 Jun 20554-207865
31 Mar 20590-98268
31 Dec 1956658169
30 Sep 1955597970
30 Jun 19532-177266
31 Mar 19500257261
31 Dec 18520266758
30 Sep 18483236550
30 Jun 18453396548
31 Mar 18475-45850
31 Dec 17476-346050
30 Sep 17489-206352
30 Jun 17521-196161
31 Mar 17500-135960
31 Dec 1647786162
30 Sep 16463116160
30 Jun 16441146352
31 Mar 16443106253
31 Dec 15453286047
30 Sep 15463295548
30 Jun 15470285043
31 Mar 15433244840
31 Dec 14415304841
30 Sep 14403574739
30 Jun 14421754938
31 Mar 14453935036

Quality Earnings: 4161 has high quality earnings.

Growing Profit Margin: 4161's current net profit margins (11.3%) are higher than last year (8.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4161's earnings have grown significantly by 62.3% per year over the past 5 years.

Accelerating Growth: 4161's earnings growth over the past year (47.5%) is below its 5-year average (62.3% per year).

Earnings vs Industry: 4161 earnings growth over the past year (47.5%) exceeded the Medical Equipment industry 5%.


Return on Equity

High ROE: 4161's Return on Equity (11.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 19:06
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bioptik Technology Incorporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
PeiChing LeeYuanta Research